Ricciarelli Roberta, Fedele Ernesto
Department of Experimental Medicine, Section of General Pathology, University of Genova, Genova, Italy.
Department of Pharmacy, Section of Pharmacology and Toxicology, University of Genova, Genova, Italy.
Curr Neuropharmacol. 2017;15(6):926-935. doi: 10.2174/1570159X15666170116143743.
Since its discovery in 1984, the beta amyloid peptide has treaded the boards of neurosciences as the star molecule in Alzheimer's disease pathogenesis. In the last decade, however, this vision has been challenged by evidence-based medicine showing the almost complete failure of clinical trials that experimented anti-amyloid therapies with great hopes. Moreover, data have accumulated which clearly indicate that this small peptide plays a key role in the physiological processes of memory formation. In the present review, we will discuss the different aspects of the amyloid cascade hypothesis, highlighting its pros and cons, and we will analyse the results of the therapeutic approaches attempted to date that should change the direction of Alzheimer's disease research in the future.
自1984年被发现以来，β淀粉样肽一直作为阿尔茨海默病发病机制中的明星分子活跃于神经科学领域。然而，在过去十年中，这种观点受到了循证医学的挑战，循证医学表明，那些曾寄予厚望的抗淀粉样蛋白疗法的临床试验几乎完全失败。此外，越来越多的数据清楚地表明，这种小肽在记忆形成的生理过程中起着关键作用。在本综述中，我们将讨论淀粉样蛋白级联假说的不同方面，突出其优点和缺点，并分析迄今为止尝试的治疗方法的结果，这些结果应该会改变未来阿尔茨海默病的研究方向。
